+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia



Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia



Vascular Health and Risk Management 6: 351-362



The last two to three decades have seen an explosive growth in interest and information regarding cardiovascular disease (CVD) risk assessment and treatment. Evidence for the role of low-density lipoprotein (LDL) in risk has led to a series of clinical guidelines/recommendations on the importance of LDL lowering with statin treatment. There is also substantial evidence on a number of lipoproteins in the initiation and progression of atherosclerosis and CV events. Health care professionals have not embraced easily novel approaches to identifying those at increased risk and more aggressive treatment. This is especially true for non-LDL factors. The use of non-statin drugs such as fibrates has been modest and many health care professionals avoid consideration of combination therapy due to an inordinate fear of toxicity. This review will attempt to provide appropriate background information on lipids/lipoproteins, including non-high density lipoprotein and risk, as well as data available on fibrates and combination pharmacologic therapy. We will review a new agent, TriLipix((R)) (fenofibric acid), and its potential role in treatment.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053229114

Download citation: RISBibTeXText

PMID: 20531954


Related references

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of Clinical Lipidology 2(6): 426-435, 2008

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27(5): 1067-1078, 2011

P296 Effects Of Fenofibric Acid In Combination With Statin Therapy On Low-Density Lipoprotein Particle Size In Patients With Mixed Dyslipidemia. Atherosclerosis Suppl.s 11(2): 79-80, 2010

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of Clinical Lipidology 3(2): 125-137, 2009

Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. American Journal of Cardiovascular Drugs 9(6): 401-409, 2009

Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis. Vascular Pharmacology 65-66: 23-30, 2015

N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. Journal of Nutritional Biochemistry 17(6): 379-384, 2006

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. American Journal of Cardiology 103(4): 515-522, 2009

Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. Journal of Lipid Research 53(11): 2425-2428, 2012

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. Journal of Clinical Lipidology 6(6): 534-544, 2013

Attainment of Goal/Desirable Lipid Levels in Patients With Mixed Dyslipidemia Following 12 Weeks of Treatment With Fenofibric Acid and Rosuvastatin Combination Therapy A Pooled Analysis of Controlled Studies. 2012

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. American Heart Journal 160(4): 759-766, 2010

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 204(1): 208-215, 2009

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovascular Drugs and Therapy 24(5-6): 421-428, 2010

The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 48(2): 396-401, 2006